These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 8043258

  • 1. Enhanced coagulation and fibrinolysis during treatment with recombinant human erythropoietin in patients undergoing chronic hemodialysis.
    Tomura S, Nakamura Y, Tachibana K, Deguchi F, Ando R, Chida Y, Marumo F.
    Blood Purif; 1993; 11(6):370-7. PubMed ID: 8043258
    [Abstract] [Full Text] [Related]

  • 2. Effects of recombinant human erythropoietin (EPOCH) on the coagulation and fibrinolytic systems and platelet function in pre-dialysis patients with chronic renal failure.
    Kaizu K, Uriu K, Eto S.
    Nihon Jinzo Gakkai Shi; 1993 Aug; 35(8):989-97. PubMed ID: 8255011
    [Abstract] [Full Text] [Related]

  • 3. Enhanced coagulation-fibrinolysis in patients on regular hemodialysis treatment.
    Nakamura Y, Chida Y, Tomura S.
    Nephron; 1991 Aug; 58(2):201-4. PubMed ID: 1830934
    [Abstract] [Full Text] [Related]

  • 4. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment.
    Tomura S, Nakamura Y, Deguchi F, Ando R, Chida Y, Marumo F.
    Thromb Res; 1991 Oct 01; 64(1):81-90. PubMed ID: 1776141
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Enhanced fibrinolytic activity during the course of hemodialysis.
    Nakamura Y, Tomura S, Tachibana K, Chida Y, Marumo F.
    Clin Nephrol; 1992 Aug 01; 38(2):90-6. PubMed ID: 1387598
    [Abstract] [Full Text] [Related]

  • 7. Cross-talk between inflammation,coagulation/fibrinolysis and vascular access in hemodialysis patients.
    Costa E, Rocha S, Rocha-Pereira P, Castro E, Reis F, Teixeira F, Miranda V, Do Sameiro Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A.
    J Vasc Access; 2008 Aug 01; 9(4):248-53. PubMed ID: 19085894
    [Abstract] [Full Text] [Related]

  • 8. [Erythropoietin and fibrinolysis in uremic patients].
    Małyszko J, Pawlak K, Mazerska M, Małyszko J, Myśliwiec M.
    Pol Arch Med Wewn; 1993 Oct 01; 90(4):267-9. PubMed ID: 8127792
    [Abstract] [Full Text] [Related]

  • 9. Plasma levels of molecular markers of blood coagulation and fibrinolysis in progressive systemic sclerosis (PSS).
    Maeda M, Kachi H, Mori S.
    J Dermatol Sci; 1996 Mar 01; 11(3):223-7. PubMed ID: 8785174
    [Abstract] [Full Text] [Related]

  • 10. Coagulation and fibrinolysis in patients with chronic renal failure on maintenance hemodialysis.
    Deguchi K, Izumi K, Noguchi M, Yuwasaki E, Suzuki H, Mori Y, Deguchi A, Ohkubo I, Tsuda M, Wada H.
    Nihon Ketsueki Gakkai Zasshi; 1989 Feb 01; 52(1):140-6. PubMed ID: 2741646
    [Abstract] [Full Text] [Related]

  • 11. Effects of a protease inhibitor, ulinastatin, on coagulation and fibrinolysis in abdominal surgery.
    Nishiyama T, Yokoyama T, Yamashita K.
    J Anesth; 2006 Feb 01; 20(3):179-82. PubMed ID: 16897236
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin.
    Malyszko J, Suchowierska E, Malyszko JS, Mysliwiec M.
    Perit Dial Int; 2002 Feb 01; 22(5):582-92. PubMed ID: 12455569
    [Abstract] [Full Text] [Related]

  • 14. [Effect of recombinant human erythropoietin on hemodynamics in chronic hemodialysis patients].
    Tomura S.
    Nihon Rinsho; 1991 Dec 01; 49 Suppl():695-701. PubMed ID: 1808338
    [No Abstract] [Full Text] [Related]

  • 15. Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation.
    Jaar B, Denis A, Viron B, Verdy E, Chamma F, Siohan P, Mignon F.
    Am J Nephrol; 1997 Dec 01; 17(5):399-405. PubMed ID: 9382155
    [Abstract] [Full Text] [Related]

  • 16. The effect of recombinant human erythropoietin on hemostasis, fibrinolysis, and blood rheology in autologous blood donors.
    Biesma DH, Bronkhorst PJ, de Groot PG, van de Wiel A, Kraaijenhagen RJ, Marx JJ.
    J Lab Clin Med; 1994 Jul 01; 124(1):42-7. PubMed ID: 8035101
    [Abstract] [Full Text] [Related]

  • 17. Recombinant human erythropoietin (rhEPO) treatment potentiates growth hormone (GH) response to growth hormone releasing hormone (GHRH) stimulation in hemodialysis patients.
    Cremagnani L, Cantalamessa L, Orsatti A, Vigna L, Vallino F, Buccianti G.
    Clin Nephrol; 1993 May 01; 39(5):282-6. PubMed ID: 8513607
    [Abstract] [Full Text] [Related]

  • 18. Fibrinolytic capacity in hemodialysis patients treated with recombinant human erythropoietin.
    Aunsholt NA, Ahlbom G, Steffensen G, Glud T.
    Nephron; 1992 May 01; 62(3):284-8. PubMed ID: 1436339
    [Abstract] [Full Text] [Related]

  • 19. Some aspects of hemostasis in CAPD patients treated with erythropoietin.
    Małyszko J, Suchowierska E, Małyszko JS, Myśliwiec M.
    Kidney Blood Press Res; 2002 May 01; 25(4):240-4. PubMed ID: 12424426
    [Abstract] [Full Text] [Related]

  • 20. Effects of recombinant human erythropoietin on hematopoietic progenitors of chronic hemodialysis patients in vitro and in vivo.
    Hino M, Miyazono K, Urabe A, Takaku F.
    Int J Cell Cloning; 1989 Jul 01; 7(4):257-63. PubMed ID: 2768843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.